AbCellera Biologics Inc.
AI summary AbCellera insiders buy open-market shares following positive Phase 2 clinical trial results for lead drug candidate ABCL635.
- Research score
- 47
- AI adjustment
- +9
Research score, not a recommendation.
Market data
Live quote and chart from Yahoo Finance, loaded through this server. Insider purchases are marked on the chart.
–
Why this score
Research score: a weighted blend of the five factors, times the routine and offering discounts, minus the selling penalty.
Why are they buying?
AI · discretionary · catalyst credible · documentedInsiders likely purchased shares following overwhelmingly positive top-line Phase 2 data for AbCellera's lead clinical candidate ABCL635, which met its primary efficacy endpoints and significantly lowered the frequency and severity of hot flashes, driving a sharp rally in the stock.
Directors and the CFO acquired shares in the open market between August 12 and August 18, 2026, shortly after the company announced trial results on August 10, 2026, that analysts described as setting a new efficacy bar for vasomotor symptoms.
Filing references and sources
- AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 (opens in a new tab)
- This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News. (opens in a new tab)
- AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes (opens in a new tab)
Stock Price & Insider Purchase History
Daily close price with open-market insider purchases plotted over time
Loading price history…
| Date | Insider | Role | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-08-12 → 2026-08-24 | Hayden Michael R history of Hayden Michael R's purchases | Director | 100,000 | $10.51 avg | $1.1M | |
| 2026-08-12 | Hayden Michael R | 46,387 | $10.37 | $481.0K | SEC filing for Hayden Michael R (opens in a new tab) | |
| 2026-08-24 | Hayden Michael R | 53,613 | $10.64 | $570.4K | SEC filing for Hayden Michael R (opens in a new tab) | |
| 2026-08-14 | Booth Andrew 4 purchases with a 63-day result · median +16.1% | CFO | 37,200 | $10.32 | $383.9K | SEC filing for Booth Andrew (opens in a new tab) |
| 2026-08-18 | Montalbano John S. 8 purchases with a 63-day result · median -1.2% | Director | 10,000 | $11.03 | $110.3K | SEC filing for Montalbano John S. (opens in a new tab) |
| Total | $1.5M | |||||
Other buying runs at ABCL
A run ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
After this run became a cluster: 21 days +10.7%63 days –126 days –
| Window | Insiders | Total | Score | 21 days | 63 days | 126 days | Status |
|---|---|---|---|---|---|---|---|
| 2022-05-12 → 2022-06-14 | 3 | $14.0M | 64 | +36.0% | +46.7% | +80.4% | closed |
| 2021-11-11 → 2021-12-03 | 3 | $5.2M | 68 | -19.2% | -33.9% | -29.0% | closed |
| 2020-12-15 | 5 | $62.4M | 55 | -0.1% | -45.9% | -69.9% | closed |